This post is from a suggested group
Physiological Risks and Ethical Considerations of Performance-Enhancing Drugs
Performance-Enhancing Drugs (PEDs) include a wide range of substances, from anabolic steroids and human growth hormone (HGH) to erythropoietin (EPO). In 2026, the scientific understanding of their long-term deleterious effects has deepened.
Anabolic steroids, while increasing muscle mass, are linked to severe cardiovascular strain, hepatic tumors, and significant endocrine disruption, including suppressed natural testosterone production and infertility.
Other substances, like EPO, increase red blood cell count to enhance oxygen delivery but simultaneously increase blood viscosity, raising the risk of stroke and myocardial infarction. Stimulants used for focus can lead to cardiac arrhythmias and severe psychological dependence. The 2026 clinical perspective emphasizes that while these substances may offer short-term physical advantages, they fundamentally compromise the body’s homeostatic balance and long-term health.